IngredientsThe common name Malay bush — more precisely Malay bush-beech — is used in English-language botanical and dietary-supplement literature to designate Gmelina arborea Roxb. (synonym: Gmelina arborea Roxb. ex Sm.). Malay bush-beech is the name of a plant defined with Gmelina arborea in various botanical sources, with references found in Ayurveda, modern medicine, and other folk traditions or local practices. A second species that appears in some databases under the bare label "Malay bush" is Psydrax dicoccos Gaertn. (synonym: Canthium dicoccum (Gaertn.) Merr., family Rubiaceae); however, the preponderance of botanical, pharmacognostic, and supplement-industry literature associates the Malay bush name with G. arborea, which is therefore the primary subject of this article. Where information specifically concerns P. dicoccos it is identified as such.
Gmelina arborea is an important medicinal plant and one of the most widely cultivated species of the family Verbenaceae. It is highly valued from time immemorial because of its vast medicinal properties. More recent taxonomic revisions place it in the family Lamiaceae; Gmelina arborea Roxb. is a fast-growing deciduous tree from the family Lamiaceae that has gathered significant attention due to its extensive medicinal value and traditional usage, particularly in Ayurvedic formulations. The genus Gmelina is one of the important genera of the family, consisting of about 33 species. The species epithet arborea derives from the Latin arbor (tree), reflecting its arboreal habit. The plant is named after a German professor of botany, Johann Georg Gmelin (1709–1755), who worked at Tübingen University.
In Ayurvedic and Indian vernacular traditions the plant carries several names: the term "Gambhari" has broad usage and comes from the Bihar tribal community; it is also referred to as "Kashmarya" and is one of the herbs included in all Ayurvedic old texts. Additional Sanskrit epithets documented in classical literature include Kashmari, Suphala, Peetarohini, Madhuparni, Sriparni, and Hira, each denoting a distinct morphological or therapeutic quality of the plant. Gmelina arborea is a deciduous tree that attains a height of up to 20 metres; the bark is greyish-white and exfoliates in thin flakes.
Gmelina arborea is most commonly found in Kashmir (India), Myanmar, Thailand, Cambodia, Vietnam, and China. In Africa it has also been introduced and naturalized; in many African countries, Gmelina arborea is traditionally used for management of arterial hypertension.
Regarding Psydrax dicoccos: Psydrax dicoccos Gaertn. (syn. Canthium dicoccum (Gaertn.) Merr., Rubiaceae) is a small evergreen tree widely distributed in evergreen, semi-evergreen and dry deciduous forests. In India it is found in the Deccan peninsula, Coromandel coastal region (Tamil Nadu, Andhra Pradesh), Maharashtra, Bihar, Assam and Meghalaya. It is commonly referred to as "Ceylon boxwood" due to its traditional usage to make wooden materials.
All major plant parts of G. arborea are used medicinally. Traditionally, various parts of Gmelina arborea, including leaves, bark, roots, and fruits, have been used in the treatment of ailments such as fever, inflammation, digestive disorders, and respiratory conditions. Common preparation forms documented in the literature include:
Gmelina arborea, or Gambhari, holds significance in Hinduism as a crucial herb in Dashamoola, known for its anti-inflammatory benefits, aiding tissue regeneration, postnatal recovery, and treating knee joint pain, reflecting its medicinal value in Ayurveda.
Gambhari is among the Dashamoola group of herbs and one of the five roots of Brihat Panchamoola, widely used for its medicinal properties since ancient times for its pain-relieving, anti-inflammatory, and analgesic properties. The Dashamoola formulation (literally "ten roots") is one of the foundational compound preparations in classical Ayurveda, described in texts including the Charaka Samhita and Ashtanga Hridayam.
Gambhari, an essential component of Dashamoola dravya, is termed to be a Rasayana dravya; medhya (memory-enhancing) activity has been related to its fruits, which are edible in nature. Its edible fruits have been linked to the benefits of Rasayana (rejuvenative), Medhya (memory enhancer), and Vrishya (aphrodisiac) in traditional medicine.
The roots are used as demulcent, lactagogue, refrigerant, stomachic, galactogogue, laxative, anthelmintic, anti-inflammatory and tonic. Gambhari has been utilized historically as an antihelmintic, antibacterial, antidiabetic, diuretic, hepatoprotective, and antiepileptic drug due to its many beneficial medical properties.
The use of Malay bush-beech (Gmelina arborea) for inflammation is primarily justified by traditional medicine practices, especially within Southeast Asia and parts of South Asia. Ethnobotanical records indicate that various parts of the plant — such as leaves, bark, and roots — have been utilised in folk medicine for their purported anti-inflammatory properties. In Ayurveda and traditional Malay medicine, decoctions or poultices prepared from the plant are sometimes applied to reduce swelling, treat wounds, or address symptoms associated with inflammation.
Traditionally used in Chinese and Ayurvedic medicine (e.g., Dashamoola), G. arborea shows promise for evidence-based integration into modern drug development.
In many African countries, Gmelina arborea is traditionally used for management of arterial hypertension. Many other usages of this plant in traditional medicine are known; for example, it is used in Nigeria and in Guinea traditional medicine to treat diarrhoea. In Nigeria (West Africa), the decoction of the leaf extract of Gmelina arborea mixed with trona is taken as a remedy for malaria fever and typhoid, as well as an antibacterial agent.
The genus Psydrax is one of the ethno-medicinally important genera of the Rubiaceae family which has only received limited scientific attention, despite coming from a pharmacologically and phytochemically important plant family. The genus has found applications in ethnomedical management of diabetes, stomach disorders, inflammations, cardiovascular diseases, epilepsy, wounds, malaria and fever. P. dicoccos, found mostly in Asia, is used in folk medicine for rheumatoid pains and asthma. Local people in the Dindigul district of Tamil Nadu use various parts of P. dicoccos to treat fever, joint and rheumatic pains, diarrhoea and inflammations.
Sixty-nine phytochemicals — including lignans, acylated iridoid glycosides, acylated rhamnopyranoses, flavonoids, flavones, and flavone glycosides — have been isolated from G. arborea. Several researchers have identified bioactive phytochemicals like luteolin and iridoid alkaloids from the leaves, hentriacontanol and lignans such as arboreol, isoarboreol, arborone, gmelanone, and gummadiol from the heartwood, and flavone glycosides in roots.
Phytochemical investigations have revealed the presence of diverse bioactive constituents, including alkaloids, flavonoids, coumarins, tannins, glycosides, and steroids, supporting its multifaceted therapeutic applications.
The constituent profile varies by plant part:
A notable nootropic constituent is gmelianoside: gmelianoside is described as the main active nootropic principal present in the extract of the G. arborea plant.
Hydroalcoholic extract of P. dicoccos leaf was recorded with high concentrations of total phenolics (59.68 ± 0.3 mg GAE/g), total flavonoids (57.85 ± 0.5 mg QRE/g) and proanthocyanidin (24.98 ± 0.17 mg AAE/g). Ethyl acetate, methanolic and aqueous extracts showed high amounts of total flavanols, vitamin E, and total tannins, respectively. GC-MS analysis facilitated the identification of 56 metabolites, with squalene and cinnamic acid as prominent compounds. Phytochemical analysis showed that the extract contained flavonoids, terpenoids, glycosides, tannins and saponins.
Direct scientific validation of traditional anti-inflammatory claims is limited. A handful of preliminary in vitro and animal studies suggest that extracts from Gmelina arborea may possess anti-inflammatory activity, potentially mediated by inhibition of pro-inflammatory mediators.
One animal study evaluated fruit extracts: the aim was to explore the anti-inflammatory activity of G. arborea fruit extracts using ethanol, ethyl acetate, n-butanol and petroleum ether as solvents; the anti-inflammatory activity was evaluated by the carrageenan-induced rat paw oedema method at a single dose of 300 mg/kg body weight. All extracts were able to show good anti-inflammatory activity in comparison with the standard drug diclofenac sodium; the anti-inflammatory activity of all the extracts was found in the order ethanol > n-butanol > petroleum ether > ethyl acetate. This is a preclinical animal study and no human clinical trials confirm these effects.
Separately, the extracts are reported to have anti-inflammatory activity, wound-healing properties, and are known to inhibit platelet aggregation. These represent in-vitro or animal-model findings.
Multiple in-vitro studies have examined radical-scavenging properties. Patil et al. (2009) investigated the antioxidant effect and free radical scavenging activity of defatted and fractionated methanol extract of stem bark of Gmelina arborea (MEGA) by using various in vitro assays; ascorbic acid was used as the reference antioxidant. A dose-dependent increase in absorbance was observed in the reducing power assay; measurement of total phenolic content using the Folin-Ciocalteu reagent showed that 1 mg of the extract contained 85.95 µg/mL total phenolics equivalent to gallic acid. The results indicate that MEGA can be a potential source of natural antioxidants, with the activity possibly attributable to the presence of phenolics.
For P. dicoccos, hydroalcoholic extract showed moderate α-amylase (IC50 of 48.94 ± 0.5 µg/mL) and α-glucosidase (IC50 of 46.98 ± 0.5 µg/mL) inhibitory activities; it is also perceived as a potent radical scavenger with reducing, metal-chelating, and total antioxidant capacity.
The aqueous extracts of the bark and fruit of Gmelina arborea have been used to study hepatoprotectant and antioxidant activity using liver slice culture, where oxidative stress was generated by H₂O₂ and paraquat. Liver slice culture offers a good model compared with isolated hepatocytes as it retains tissue organisation and cell-to-cell matrix interactions. The extracts also displayed antioxidant activity in in-vitro radical scavenging assays. Results indicate that Gmelina bark and fruit extracts protected liver slice culture cells by alleviating oxidative stress–induced damage.
These hepatoprotective findings are from an in-vitro model. Iridoid glycosides from flowers of Gmelina arborea have also been reported to exhibit good hepatoprotective activity. No controlled human clinical trials on hepatoprotection have been published.
Gmelina arborea Roxb. (Family: Verbenaceae) is a medicinal plant that has been used in the treatment of diabetes mellitus since ancient times; decoctions prepared from various parts of G. arborea are used in traditional systems of medicine as a remedy against diabetes mellitus and various other diseases. Mechanistically, the antidiabetic potential has been explored through enzyme inhibition assays, particularly inhibition of α-amylase and α-glucosidase, which slow carbohydrate digestion and post-prandial glucose uptake. No human randomised controlled trials have been published to date.
Leaves and fruit extracts of Gmelina showed antibacterial and antifungal activity against different pathogenic organisms. Gmelina arborea showed antifungal activity against Trametes versicolor. These are in-vitro findings; clinical evidence is absent.
Animal model studies have examined pain-related endpoints. In the acetic acid–induced writhing test, the extract significantly reduced the number of writhes at 100 and 200 mg/kg but not so much at 50 mg/kg; in the formalin-induced paw lick test, the effect was similar; the analgesic effects were comparable to that of indomethacin used at 10 mg/kg. These are preclinical rodent-model results.
The extracts are reported to have wound-healing and antidiarrheal properties. Wound-healing properties have been demonstrated in animal model studies. All available evidence is from animal studies; no human clinical wound-healing trials exist.
Several pharmacological properties including antimicrobial, antidiabetic, antioxidant, and vasodilating activities have been described for Gmelina arborea. A study cited in the literature examined the antihypertensive effects of G. arborea aqueous leaf extract fractions in Wistar rats, with the butanol fraction showing antihypertensive properties; however, these data are from in-vivo animal models.
Gmelina arborea exhibits a wide range of beneficial effects, including antioxidant, hepatoprotective, anticancer, neuroprotective, anti-tumour, cardioprotective, anticonvulsant and antihyperlipidemic activities. The presence of gmelianoside is specifically linked to nootropic or cognitive-enhancing potential, but evidence is limited to preclinical or pharmacognostic characterisation; no human cognitive trials have been reported.
Gmelina arborea extracts possess powerful antioxidant and cytotoxic activities, which fall within the American Cancer Institute criteria. For P. dicoccos, a study focused on Psydrax dicoccos Gaertn., an evergreen tree abundantly distributed in Tamil Nadu (India), for its possible application against breast cancer cells; the P. dicoccos leaf methanol extract demonstrated cytotoxic effects against MCF7 breast cancer cells at IC50 of 34 μg/mL. These are in-vitro cell-line findings and do not constitute clinical evidence of anticancer efficacy.
Antioxidant assays and histopathological studies have been conducted to confirm the protective effects of ethanolic extracts against doxorubicin-induced cardiotoxicity in rats. This is an in-vivo animal model; clinical cardioprotective evidence is absent.
Many G. arborea mixtures have been recorded in Ayurvedic medicinal plant databases to cure a variety of ailments. Dashamoolarishtam is reported to exhibit anti-inflammatory, anti-arthritic, pro-digestive, antibacterial, antioxidant, anti-stress, and antidepressant properties. Red blood cell production and haemoglobin levels are also reported to be increased by it. These reports derive from traditional monographs and preliminary studies on the polyherbal compound, not on G. arborea as an isolated ingredient.
While there is substantial ethnobotanical documentation of its role in folk remedies, scientific validation remains limited. Few studies have investigated the anti-inflammatory properties of Malay bush; some in-vitro research suggests possible bioactivity, but robust clinical or pharmacological evidence is lacking. Available data are mostly anecdotal or based on traditional knowledge rather than rigorous scientific trials.
Evidence strength: Weak — preclinical (animal/in-vitro) only; no human trials.
Multiple in-vitro studies across multiple solvent extracts and plant parts consistently demonstrate radical-scavenging capacity, with the activity attributed to the phenolic content. Findings are reproducible across independent laboratories but remain in-vitro. Evidence strength: Preliminary — consistent in vitro; no clinical trials.
Traditional use for blood sugar management is supported by enzyme-inhibition assays (α-amylase, α-glucosidase) and animal model studies, but no human randomised controlled trials have been conducted. Evidence strength: Weak — animal/in-vitro only.
In-vitro liver slice culture data and isolated flower iridoid glycoside studies show protection against oxidative hepatic damage. Evidence strength: Preliminary — in-vitro only.
Animal studies (rat wound model) report accelerated healing with leaf extracts. Evidence strength: Weak — animal models only; no controlled clinical evidence.
In-vitro minimum inhibitory concentration studies document activity against various bacteria and fungi. Evidence strength: Preliminary — in-vitro only.
Animal model data (Wistar rat) support vasodilating and blood-pressure-lowering effects. Evidence strength: Weak — animal models only.
Pharmacognostic identification of gmelianoside as a putative nootropic principal, along with traditional Rasayana and Medhya designations, constitutes the basis of this claim. No human cognitive trials exist. Evidence strength: Very preliminary — traditional use and chemical characterisation only.
Though attempts have been made since 1970 to isolate compounds from this species, there has been no consistent effort to understand the different molecules produced by the plant, its mode of action, nor investigations on the pharmacological value related to information available on its phytochemistry. Cytotoxic activity against cancer cell lines (in-vitro) has been reported for both G. arborea and P. dicoccos. Evidence strength: Very preliminary — in-vitro cell-line data only; no clinical oncology evidence.
Based on the available preclinical and traditional literature, the following body systems are associated with G. arborea preparations:
No standardised or regulatory-approved dosage exists for Gmelina arborea as an isolated dietary supplement. The following dosage information appears in the primary research literature:
No human clinical dose-finding or dose-ranging studies have been published. Traditional Ayurvedic practice administers bark decoctions and powders according to classical formulary weights (not validated by modern clinical trials). Dosages used in classical formulations such as Dashamoola are those of the compound preparation, not G. arborea in isolation.
Toxicological studies indicate a favourable safety profile within therapeutic doses. The primary published toxicological data are from rodent studies:
The aqueous extract did not produce mortality, changes in behaviour, or any other physiological abnormalities in mice at any of the selected doses. There were no significant differences in body weight, organ weights, or feeding habits across the tested dose range. These findings come from a 28-day repeated-dose rodent study; extrapolation to humans requires caution.
A methanol extract toxicity study (designed to evaluate acute and repeated dose toxicity of the methanol extract of Gmelina arborea stem bark) administered the extract orally to Swiss albino mice at a dose range of 300–5000 mg/kg for acute toxicity, and to Wistar rats at 300, 1000, and 2000 mg/kg/day for 28 days; the effects on body weight, food and water consumption, organ weight, haematology, clinical chemistry, and histology were studied.)
There is little toxicological information available regarding the safety of Gmelina arborea after human exposure. No controlled human safety studies, pharmacokinetic studies in humans, or post-marketing surveillance datasets have been published in indexed literature.
Despite preliminary findings, the overall body of scientific evidence is sparse and lacks rigorous controlled evaluation. The plant's long history of use in Ayurveda and other traditional systems suggests a degree of empirical tolerability, but this cannot substitute for formal clinical safety evaluation.
Extracts of G. arborea are known to inhibit platelet aggregation. This pharmacological property, demonstrated in preclinical studies, raises a theoretical concern regarding additive effects when the plant is used alongside antiplatelet drugs or anticoagulants; no clinical interaction studies have been conducted to confirm or quantify this risk.
Given documented antihypertensive effects in animal models, the theoretical possibility of additive hypotensive effects with antihypertensive pharmaceuticals exists. No clinical data are available to characterise this interaction in humans.
The name "Malay bush" is applied variably to Gmelina arborea and to Psydrax dicoccos in different regional and commercial contexts. Malay bush (Psydrax dicoccos or similar species, depending on local nomenclature) is primarily used in traditional medicine systems, particularly in parts of Southeast Asia. This nomenclatural ambiguity creates a risk of misidentification in supplement supply chains, with consequent variation in phytochemical composition and unpredictable biological activity.
Gmelina arborea exhibits multiple therapeutic activities, including antimicrobial, antioxidant, anti-inflammatory, antidiabetic, hepatoprotective, analgesic, and neuroprotective effects, validated by in vitro and in vivo studies. However, the entire body of pharmacological evidence rests on in-vitro assays and animal models. The use of Malay bush for inflammation — and by extension its other proposed indications — is justified by traditional use, supported by historical practice and some preliminary pharmacological indications, but lacks strong, peer-reviewed scientific backing. More comprehensive studies are needed to confirm efficacy and safety.
Though attempts have been made since 1970 to isolate compounds from this species, there has been no consistent effort to understand the different molecules produced by the plant, its mode of action, nor investigations on the pharmacological value related to information available on its phytochemistry.
For P. dicoccos, the genus Psydrax is one of the ethno-medicinally important genera of the Rubiaceae family which has only received limited scientific attention, despite coming from a pharmacologically and phytochemically important plant family. Psydrax has 130 species, with only 8% documented for ethnomedicinal uses.
Key research gaps include: absence of any human clinical trials for either species; lack of pharmacokinetic data in humans; no standardisation of extract specifications for dietary supplement use; no formal drug interaction studies; and limited identification of specific molecular targets mediating the observed preclinical activities.
Health conditions that Malay bush may help support.
Body systems that Malay bush may help support.
Go back